Halozyme Announces argenx Receives European Commission Approval of VYVGART SC With ENHANZE For Generalized Myasthenia Gravis
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics, Inc. announced that argenx has received approval from the European Commission for VYVGART SC, a subcutaneous treatment for Generalized Myasthenia Gravis, which uses Halozyme's ENHANZE drug delivery technology.
November 16, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme's ENHANZE technology is part of the newly approved VYVGART SC by argenx, potentially increasing Halozyme's royalty revenues and strengthening its market position.
The approval of VYVGART SC in the European market is likely to lead to increased usage of Halozyme's ENHANZE technology, which can result in higher royalty revenues for Halozyme. This approval also validates the effectiveness of ENHANZE, potentially leading to more partnerships and a stronger competitive position in the market.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80